From: Circulating tumor cells in newly diagnosed inflammatory breast cancer
 | Stage III IBC | Metastatic IBC | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Characteristic | N | % | ≥1 CTC a | % | ≥ 5 CTC a | % | N | % | ≥ 1 CTC a | % | ≥ 5 CTC a | % |
All patients | 77 | 100.0 | 42 | 54.5 | 15 | 19.5 | 70 | 100.0 | 59 | 84.3 | 32 | 45.7 |
Histology | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Infiltrative ductal carcinoma | 74 | 96.1 | 40 | 54.1 | 15 | 20.3 | 66 | 94.3 | 55 | 83.3 | 31 | 47.0 |
Other histology | 3 | 3.9 | 2 | 66.7 | 0 | 0.00 | 4 | 5.7 | 4 | 100.0 | 1 | 25.0 |
P value | Â | Â | Â | 1.00 | Â | 0.61 | Â | Â | Â | 0.61 | Â | 0.62 |
ER/PR status | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Positive for either | 43 | 55.8 | 19 | 44.2 | 5 | 11.6 | 40 | 57.1 | 33 | 82.5 | 20 | 50.0 |
Negative for both | 34 | 44.2 | 23 | 67.6 | 10 | 29.4 | 30 | 42.9 | 26 | 86.7 | 12 | 40.0 |
P value | Â | Â | Â | 0.06 | Â | 0.08 | Â | Â | Â | 0.74 | Â | 0.47 |
HER-2/neu status | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Overexpressed | 26 | 33.8 | 17 | 65.4 | 7 | 26.9 | 19 | 27.1 | 13 | 68.4 | 9 | 47.4 |
Negative | 51 | 66.2 | 25 | 49.0 | 8 | 15.7 | 51 | 72.9 | 46 | 90.2 | 23 | 45.1 |
P value | Â | Â | Â | 0.23 | Â | 0.36 | Â | Â | Â | 0.04 | Â | 1.00 |
Grade | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
High grade | 55 | 71.4 | 32 | 58.2 | 11 | 20.0 | 53 | 75.7 | 43 | 81.1 | 24 | 45.3 |
Intermediate/low grade | 22 | 28.6 | 10 | 45.5 | 4 | 18.2 | 15 | 21.4 | 14 | 93.3 | 8 | 53.3 |
Unknown | - | - | - | - | - | - | 2 | 2.9 | 2 | - | 0 | - |
P value | Â | Â | Â | 0.31 | Â | 1.00 | Â | Â | Â | 0.43 | Â | 0.77 |
ER/PR and HER2/neu status | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Triple receptor negative | 19 | 24.7 | 12 | 63.2 | 5 | 26.3 | 19 | 27.1 | 17 | 89.5 | 7 | 36.8 |
Not-triple receptor negative | 58 | 75.3 | 30 | 51.7 | 10 | 17.2 | 51 | 72.9 | 42 | 82.4 | 25 | 49.0 |
P value | Â | Â | Â | 0.44 | Â | 0.50 | Â | Â | Â | 0.71 | Â | 0.43 |
Sites of metastases | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Non-visceral | - | - | - | - | - | - | 42 | 60.0 | 34 | 81.0 | 18 | 42.9 |
Visceral | - | - | - | - | - | - | 28 | 40.0 | 25 | 89.3 | 14 | 50.0 |
P value | Â | Â | Â | Â | Â | Â | Â | Â | Â | 0.50 | Â | 0.63 |
Bone metastasis | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Present | - | - | - | - | - | - | 39 | 55.7 | 32 | 82.1 | 19 | 48.7 |
Absent | - | - | - | - | - | - | 31 | 44.3 | 27 | 87.1 | 13 | 41.9 |
P value | Â | Â | Â | Â | Â | Â | Â | Â | Â | 0.70 | Â | 0.63 |
Number of metastases | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
1 | - | - | - | - | - | - | 29 | 41.4 | 22 | 75.9 | 13 | 44.8 |
≥2 | - | - | - | - | - | - | 41 | 58.6 | 37 | 90.2 | 19 | 46.3 |
P value | Â | Â | Â | Â | Â | Â | Â | Â | Â | 0.20 | Â | 1.00 |
Statin use | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
No-statins | 62 | 80.5 | 39 | 62.9 | 14 | 22.6 | 60 | 85.7 | 51 | 85.0 | 30 | 50.0 |
L-statinsb | 7 | 9.1 | 1 | 14.3 | 1 | 14.3 | 5 | 7.1 | 5 | 100.0 | 1 | 20.0 |
H-statinsb | 8 | 10.4 | 2 | 25.0 | 0 | 0.0 | 5 | 7.1 | 3 | 60.0 | 1 | 20.0 |
P value | Â | Â | Â | 0.01 | Â | 0.30 | Â | Â | Â | 0.20 | Â | 0.21 |
Menopausal status | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Premenopausal | 27 | 35.1 | 19 | 70.4 | 9 | 33.3 | 25 | 35.7 | 21 | 84.0 | 13 | 52.0 |
Postmenopausal | 50 | 64.9 | 23 | 46.0 | 6 | 12.0 | 45 | 64.3 | 38 | 84.4 | 19 | 42.2 |
P value | Â | Â | Â | 0.06 | Â | 0.03 | Â | Â | Â | 1.00 | Â | 0.46 |
Lymphovascular tumor emboli | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Present | 36 | 46.8 | 20 | 55.6 | 9 | 25.0 | 42 | 60.0 | 37 | 88.1 | 17 | 40.5 |
Absent | 40 | 51.9 | 21 | 52.5 | 6 | 15.0 | 24 | 34.3 | 18 | 75.0 | 12 | 50.0 |
Unknown | 1 | 1.3 | 1 | - | 0 | - | 4 | 5.7 | 4 | - | 3 | - |
P value | Â | Â | Â | 0.64 | Â | 0.39 | Â | Â | Â | 0.19 | Â | 0.61 |